Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2038239

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2038239

Hematology Analyzers and Reagents Market by Product & Service, Price (High, Mid, Low), Application (Infectious Diseases, Blood Cancer), End User (Hospital, CTL, Govt Lab) - Global Forecast to 2031

PUBLISHED:
PAGES: 292 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

The global hematology analyzers and reagents market is projected to reach USD 10.33 billion by 2031 from USD 7.57 billion in 2026, growing at a CAGR of 6.4% during the forecast period.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsProduct and Service, Price Range, Application, Usage Type, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Advancements in hematology analyzers and reagents are expected to be a primary driver of market growth in the coming years. However, the high costs of hematology analyzers and reagents, the shortage of skilled experts in emerging nations, and the slow adoption of advanced hematology devices in these regions could hinder growth in the hematology analyzers and reagents market.

Hematology Analyzers and Reagents Market - IMG1

"The hematology products and services segment held the largest share of the market in 2025."

The global market for hematology analyzers and reagents, by product and service, is segmented into hematology products & services, hemostasis products & services, and immunohematology products & services. Hematology products & services hold a dominant position in the global market for hematology analyzers and reagents. This segment is further divided into: instruments, reagents, consumables, and services. Factors driving growth include higher test volumes, rising prevalence of hematological conditions, and technological advancements such as the introduction of five- and six-part differential analyzers, flow cytometry, and artificial intelligence.

"The low-range hematology analyzers segment held the largest share of the market in 2025."

Based on price range, the hematology analyzers and reagents market is segmented into high-range hematology analyzers, mid-range hematology analyzers, and low-range hematology analyzers. It is anticipated that the market will be led by the low-range hematology analyzers segment throughout the forecast period. The anticipation of the dominance of the low-range hematology analyzer segment stems from its cost-effectiveness and ability to perform well in limited-resource environments, such as small labs and diagnostic centers. They come with a 3-part differential, small in size, smaller sample volumes, and are easy to operate.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-40%, Tier 2-30%, and Tier 3- 30%
  • By Designation: C-level-27%, Director-level-18%, and Others-55%
  • By Region: North America-40%, Europe-32%, Asia Pacific-20%, Latin America-5%, and the Middle East & Africa-3%

The prominent players in the hematology analyzers and reagents market are F. Hoffmann-La Roche Ltd (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Diatron (Hungary), Drew Scientific (US), Siemens Healthineers (Germany), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Horiba Ltd. (Japan), Nihon Kohden Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), BioSystems (Spain), and QuidelOrtho Corporation (US), among others.

Research Coverage

This report studies the hematology analyzers and reagents market based on product and service, price range, application, end user, and region. It also covers the factors driving market growth, analyzes the opportunities and challenges in the market, and provides details on the competitive landscape for market leaders. Furthermore, the report analyzes micro markets by their individual growth trends and forecasts revenue for the market segments across five main regions (and the respective countries within these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market presence.

This report provides insights into the following pointers:

  • Analysis of key drivers (rapid integration of AI technology for increased accuracy of diagnosis and optimized hematology analysis workflows, advanced parameters and multi-functionality behind increasing use of hematology analyzers, growing requirements for affordable and efficient tests with first-pass yield and less reagents usage), restraints (expensive advanced hematology analyzer instruments hampering their implementation in healthcare institutions and limited accuracy of digital morphology analyzers in identifying abnormal cells), opportunities (expanding use of AI-based telehematology solutions and precision diagnostics offering advanced cell analysis and rare cell detection capabilities), and challenges (Increased complexity of data management and analysis due to the advent of next-generation hematology analyzers and laboratory shortages affecting workflow efficiency of hematology) influencing the growth of the contrast media market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in hematology analyzers and reagents market
  • Market Development: Comprehensive information about lucrative markets-the report analyses the hematology analyzers and reagents market across varied regions
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the hematology analyzers and reagents market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players

Product Code: MD 2479

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
  • 2.4 HIGH-GROWTH SEGMENTS
  • 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
  • 3.2 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION
  • 3.3 HEMATOLOGY ANALYZERS AND REAGENTS MARKET IN ASIA PACIFIC, BY END USER AND COUNTRY
  • 3.4 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY GEOGRAPHY

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Rapid integration of AI to enhance diagnostic accuracy and optimize hematology workflows
      • 4.2.1.2 Growing preference for high-parameter and multi-functional testing
      • 4.2.1.3 Mounting demand for cost-efficient hematology analyzers
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 High cost of advanced hematology analyzers
      • 4.2.2.2 Limited accuracy of digital morphology analyzers in detecting rare and complex cell abnormalities
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Expansion of AI-enabled tele-hematology and remote diagnostics
      • 4.2.3.2 Adoption of precision diagnostics enabling advanced cell profiling, rare cell detection, and early disease identification
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Complexity in managing and interpreting data generated by next-generation hematology analyzers
      • 4.2.4.2 Shortage of laboratory workforce
  • 4.3 UNMET NEEDS
  • 4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 BARGAINING POWER OF SUPPLIERS
    • 5.1.4 THREAT OF NEW ENTRANTS
    • 5.1.5 THREAT OF SUBSTITUTES
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 5.2.3 MACROECONOMIC OUTLOOK FOR EUROPE
    • 5.2.4 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 5.2.5 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 5.2.6 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 5.2.7 TRENDS IN GLOBAL IN-VITRO DIAGNOSTICS (IVD) INDUSTRY
    • 5.2.8 TRENDS IN GLOBAL POINT-OF-CARE (POC) DIAGNOSTICS INDUSTRY
  • 5.3 VALUE CHAIN ANALYSIS
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 PRICING ANALYSIS
    • 5.5.1 PRICING TREND OF HEMATOLOGY INSTRUMENTS, BY REGION, 2023-2025
    • 5.5.2 AVERAGE SELLING PRICE OF HEMATOLOGY ANALYZERS AND REAGENTS, BY PRICE RANGE, 2025
  • 5.6 TRADE DATA ANALYSIS
    • 5.6.1 IMPORT DATA (HS CODE 902780)
    • 5.6.2 EXPORT DATA (HS CODE 902780)
  • 5.7 KEY CONFERENCES AND EVENTS, 2026-2027
  • 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.9 INVESTMENT AND FUNDING SCENARIO
  • 5.10 CASE STUDY ANALYSIS
    • 5.10.1 DETECTION OF ABNORMAL WBC POPULATIONS IN HIGH WBC COUNT CASES USING XN-SERIES AUTOMATED HEMATOLOGY ANALYZER
    • 5.10.2 MONITORING AND DETECTION OF ACUTE MYELOBLASTIC LEUKEMIA (AML-M1) USING ADVANCED HEMATOLOGY ANALYZERS
    • 5.10.3 DETECTION OF MICROCYTIC ANEMIA WITH THROMBOCYTOSIS THROUGH ADVANCED SCATTERGRAM ANALYSIS
  • 5.11 IMPACT OF US TARIFFS - HEMATOLOGY ANALYZERS AND REAGENTS MARKET
    • 5.11.1 INTRODUCTION
    • 5.11.2 KEY TARIFF RATES
    • 5.11.3 PRICE IMPACT ANALYSIS
    • 5.11.4 IMPACT ON COUNTRIES/REGIONS
      • 5.11.4.1 US
      • 5.11.4.2 Europe
      • 5.11.4.3 Asia Pacific
    • 5.11.5 IMPACT ON END USERS

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACTS, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY TECHNOLOGIES
    • 6.1.1 FLOW CYTOMETRY
    • 6.1.2 DIGITAL MORPHOLOGY ANALYZERS
    • 6.1.3 MICROFLUIDICS
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 LABORATORY INFORMATION SYSTEMS
    • 6.2.2 CLOUD & REMOTE DIAGNOSTICS
  • 6.3 PATENT ANALYSIS
  • 6.4 FUTURE APPLICATIONS
  • 6.5 IMPACT OF AI/GEN AI ON HEMATOLOGY ANALYZERS AND REAGENTS MARKET
    • 6.5.1 TOP USE CASES AND MARKET POTENTIAL
    • 6.5.2 BEST PRACTICES FOLLOWED BY COMPANIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
    • 6.5.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
    • 6.5.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS
    • 6.5.5 CLIENTS' READINESS TO ADOPT AI/GEN AI-INTEGRATED HEMATOLOGY ANALYZERS AND REAGENTS
  • 6.6 SUCCESS STORIES AND REAL-WORLD APPLICATIONS

7 REGULATORY LANDSCAPE

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 REGULATORY TRENDS

8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 KEY STAKEHOLDERS IN BUYING PROCESS AND EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS OF VARIOUS END USERS

9 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE

  • 9.1 INTRODUCTION
  • 9.2 LOW-RANGE HEMATOLOGY ANALYZERS
    • 9.2.1 LOW OPERATING EXPENSES TO ACCELERATE SEGMENTAL GROWTH
  • 9.3 HIGH-RANGE HEMATOLOGY ANALYZERS
    • 9.3.1 HIGH ACCURACY AND MULTI-PARAMETER APPROACH TO FUEL SEGMENTAL GROWTH
  • 9.4 MID-RANGE HEMATOLOGY ANALYZERS
    • 9.4.1 INTEGRATION WITH QUALITY CONTROL SOFTWARE TO SUPPORT SEGMENTAL GROWTH

10 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE

  • 10.1 INTRODUCTION
  • 10.2 STANDALONE ANALYZERS
    • 10.2.1 INCREASING DEMAND FOR HIGH-THROUGHPUT AND AUTOMATED LABORATORY WORKFLOWS TO FOSTER SEGMENTAL GROWTH
  • 10.3 POINT-OF-CARE ANALYZERS
    • 10.3.1 SHIFTING PREFERENCE TOWARD DECENTRALIZED AND RAPID DIAGNOSTICS TO EXPEDITE SEGMENTAL GROWTH

11 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE

  • 11.1 INTRODUCTION
  • 11.2 HEMATOLOGY PRODUCTS & SERVICES
    • 11.2.1 REAGENTS & CONSUMABLES
      • 11.2.1.1 Hematology reagents
        • 11.2.1.1.1 Growing preference for rental business models to drive market
      • 11.2.1.2 Hematology consumables
        • 11.2.1.2.1 Requirement for accurate and efficient blood analysis in laboratory workflows to spur demand
      • 11.2.1.3 Controls & calibrators
        • 11.2.1.3.1 Ability to monitor multiple parameters to boost segmental growth
      • 11.2.1.4 Slide stainers & makers
        • 11.2.1.4.1 Detailed visualization of cellular morphology to augment segmental growth
    • 11.2.2 INSTRUMENTS
      • 11.2.2.1 5-part & 6-part fully automated hematology analyzers
        • 11.2.2.1.1 Identification and classification of WBCs to drive market
      • 11.2.2.2 3-part fully automated hematology analyzers
        • 11.2.2.2.1 Low maintenance costs to contribute to segmental growth
      • 11.2.2.3 Point-of-care & semi-automated testing hematology analyzers
        • 11.2.2.3.1 Shift toward decentralized, rapid, and multi-parameter hematology testing to spur demand
    • 11.2.3 SERVICES
      • 11.2.3.1 High adoption of diagnostic techniques to boost segmental growth
  • 11.3 HEMOSTASIS PRODUCTS & SERVICES
    • 11.3.1 HEMOSTASIS REAGENTS & CONSUMABLES
      • 11.3.1.1 Expanding use in comprehensive coagulation testing and specialized diagnostics to fuel segmental growth
    • 11.3.2 HEMOSTASIS INSTRUMENTS
      • 11.3.2.1 High productivity with low complexities to drive market
    • 11.3.3 HEMOSTASIS SERVICES
      • 11.3.3.1 Advancements in hemostasis diagnostic techniques to support segmental growth
  • 11.4 IMMUNOHEMATOLOGY PRODUCTS & SERVICES
    • 11.4.1 IMMUNOHEMATOLOGY REAGENTS & CONSUMABLES
      • 11.4.1.1 Use to ensure accurate transfusion testing and enhance blood safety to bolster segmental growth
    • 11.4.2 IMMUNOHEMATOLOGY INSTRUMENTS
      • 11.4.2.1 Growing automation in immunohematology labs to foster segmental growth
    • 11.4.3 SERVICES
      • 11.4.3.1 Provision of customer-focused care to support segmental growth

12 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION

  • 12.1 INTRODUCTION
  • 12.2 HEMORRHAGIC CONDITIONS
    • 12.2.1 INCREASING DEMAND FOR DECENTRALIZED AND FREQUENT MONITORING TO EXPEDITE SEGMENTAL GROWTH
  • 12.3 INFECTIOUS DISEASES
    • 12.3.1 NEED FOR RAPID SCREENING TO ACCELERATE SEGMENTAL GROWTH
  • 12.4 IMMUNE SYSTEM DISORDERS
    • 12.4.1 FOCUS ON ADVANCED BLOOD PROFILING TO FACILITATE SEGMENTAL GROWTH
  • 12.5 BLOOD CANCER
    • 12.5.1 ABILITY TO IDENTIFY ABNORMAL BLOOD CELLS AND MORPHOLOGICAL ABNORMALITIES TO DRIVE MARKET
  • 12.6 ANEMIA
    • 12.6.1 SHIFT TOWARD ADVANCED RBC PARAMETER ANALYSIS TO BOOST SEGMENTAL GROWTH
  • 12.7 OTHER APPLICATIONS

13 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER

  • 13.1 INTRODUCTION
  • 13.2 COMMERCIAL SERVICE PROVIDERS
    • 13.2.1 HIGH EMPHASIS ON HIGH-VOLUME ROUTINE TESTING, PREVENTIVE SCREENING, AND ADVANCED DIAGNOSTICS TO DRIVE MARKET
  • 13.3 HOSPITAL LABORATORIES
    • 13.3.1 RISING NEED FOR REAL-TIME PATIENT DIAGNOSIS AND EMERGENCY TESTING TO EXPEDITE SEGMENTAL GROWTH
  • 13.4 GOVERNMENT REFERENCE LABORATORIES
    • 13.4.1 INCREASING NEED FOR LARGE-SCALE DISEASE SURVEILLANCE, SCREENING, AND DIAGNOSTIC STANDARDIZATION TO SPUR DEMAND
  • 13.5 RESEARCH & ACADEMIC INSTITUTES
    • 13.5.1 GROWING FOCUS ON ADVANCED DISEASE PROFILING, BIOMARKER DISCOVERY, AND TRANSLATIONAL RESEARCH TO BOOST SEGMENTAL GROWTH

14 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION

  • 14.1 INTRODUCTION
  • 14.2 NORTH AMERICA
    • 14.2.1 US
      • 14.2.1.1 Rising incidence of anemia and hemophilia to drive market
    • 14.2.2 CANADA
      • 14.2.2.1 Mounting demand for accurate blood diagnostics to bolster market growth
  • 14.3 EUROPE
    • 14.3.1 GERMANY
      • 14.3.1.1 Increasing prevalence of anemia to contribute to market growth
    • 14.3.2 FRANCE
      • 14.3.2.1 Rising adoption of automated and high-throughput hematology analyzers to support market growth
    • 14.3.3 UK
      • 14.3.3.1 High incidence of blood-related disorders to expedite market growth
    • 14.3.4 ITALY
      • 14.3.4.1 Growing acceptance of hematology-based diagnostics to boost market growth
    • 14.3.5 SPAIN
      • 14.3.5.1 Rising preference for automated and high-throughput hematology systems to augment market growth
    • 14.3.6 REST OF EUROPE
  • 14.4 ASIA PACIFIC
    • 14.4.1 CHINA
      • 14.4.1.1 Large target patient population to expedite market growth
    • 14.4.2 JAPAN
      • 14.4.2.1 Rising cases of influenza to support market growth
    • 14.4.3 INDIA
      • 14.4.3.1 Government-led procurement initiatives and expanding diagnostic infrastructure to fuel market growth
    • 14.4.4 AUSTRALIA
      • 14.4.4.1 Increasing prevalence of celiac disease to drive market
    • 14.4.5 SOUTH KOREA
      • 14.4.5.1 Strong focus on advanced diagnostics and automation to contribute to market growth
    • 14.4.6 REST OF ASIA PACIFIC
  • 14.5 LATIN AMERICA
    • 14.5.1 BRAZIL
      • 14.5.1.1 Increasing burden of anemia and infectious diseases to expedite market growth
    • 14.5.2 MEXICO
      • 14.5.2.1 Mounting demand for diagnostic testing to accelerate market growth
    • 14.5.3 REST OF LATIN AMERICA
  • 14.6 MIDDLE EAST & AFRICA
    • 14.6.1 HIGH DISEASE AWARENESS, IMPROVING HEALTHCARE INFRASTRUCTURE, AND ADVANCED TREATMENT OPTIONS TO DRIVE MARKET
    • 14.6.2 GCC COUNTRIES
    • 14.6.3 REST OF MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE

  • 15.1 OVERVIEW
  • 15.2 KEY PLAYERS COMPETITIVE STRATEGIES/RIGHT TO WIN, 2022-2026
  • 15.3 REVENUE ANALYSIS, 2021-2025
  • 15.4 MARKET SHARE ANALYSIS, 2025
  • 15.5 MARKET RANKING, 2025
  • 15.6 COMPANY VALUATION AND FINANCIAL METRICS
  • 15.7 PRODUCT COMPARISON
  • 15.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 15.8.1 STARS
    • 15.8.2 EMERGING LEADERS
    • 15.8.3 PERVASIVE PLAYERS
    • 15.8.4 PARTICIPANTS
    • 15.8.5 COMPETITIVE FOOTPRINT: KEY PLAYERS, 2025
      • 15.8.5.1 Company footprint
      • 15.8.5.2 Region footprint
      • 15.8.5.3 Product & service footprint
      • 15.8.5.4 Application footprint
      • 15.8.5.5 End user footprint
  • 15.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 15.9.1 PROGRESSIVE COMPANIES
    • 15.9.2 RESPONSIVE COMPANIES
    • 15.9.3 DYNAMIC COMPANIES
    • 15.9.4 STARTING BLOCKS
    • 15.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
      • 15.9.5.1 Detailed list of key startups/SMEs
      • 15.9.5.2 Competitive benchmarking of key startups/SMEs
  • 15.10 COMPETITIVE SCENARIO
    • 15.10.1 PRODUCT LAUNCHES AND APPROVALS
    • 15.10.2 DEALS
    • 15.10.3 EXPANSIONS

16 COMPANY PROFILES

  • 16.1 KEY PLAYERS
    • 16.1.1 SYSMEX CORPORATION
      • 16.1.1.1 Business overview
      • 16.1.1.2 Products offered
      • 16.1.1.3 Recent developments
        • 16.1.1.3.1 Deals
        • 16.1.1.3.2 Expansions
      • 16.1.1.4 MnM view
        • 16.1.1.4.1 Right to win
        • 16.1.1.4.2 Strategic choices
        • 16.1.1.4.3 Weaknesses and competitive threats
    • 16.1.2 ABBOTT
      • 16.1.2.1 Business overview
      • 16.1.2.2 Products offered
      • 16.1.2.3 Recent developments
        • 16.1.2.3.1 Product launches and approvals
      • 16.1.2.4 MnM view
        • 16.1.2.4.1 Right to win
        • 16.1.2.4.2 Strategic choices
        • 16.1.2.4.3 Weaknesses and competitive threats
    • 16.1.3 DANAHER CORPORATION
      • 16.1.3.1 Business overview
      • 16.1.3.2 Products offered
      • 16.1.3.3 Recent developments
        • 16.1.3.3.1 Deals
      • 16.1.3.4 MnM view
        • 16.1.3.4.1 Right to win
        • 16.1.3.4.2 Strategic choices
        • 16.1.3.4.3 Weaknesses and competitive threats
    • 16.1.4 SIEMENS HEALTHINEERS AG
      • 16.1.4.1 Business overview
      • 16.1.4.2 Products offered
      • 16.1.4.3 Recent developments
        • 16.1.4.3.1 Product launches and approvals
        • 16.1.4.3.2 Deals
      • 16.1.4.4 MnM view
        • 16.1.4.4.1 Right to win
        • 16.1.4.4.2 Strategic choices
        • 16.1.4.4.3 Weaknesses and competitive threats
    • 16.1.5 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
      • 16.1.5.1 Business overview
      • 16.1.5.2 Products offered
      • 16.1.5.3 Recent developments
        • 16.1.5.3.1 Product launches and approvals
      • 16.1.5.4 MnM view
        • 16.1.5.4.1 Right to win
        • 16.1.5.4.2 Strategic choices
        • 16.1.5.4.3 Weaknesses and competitive threats
    • 16.1.6 DIATRON
      • 16.1.6.1 Business overview
      • 16.1.6.2 Products offered
      • 16.1.6.3 Recent developments
        • 16.1.6.3.1 Expansions
    • 16.1.7 DREW SCIENTIFIC
      • 16.1.7.1 Business overview
      • 16.1.7.2 Products offered
    • 16.1.8 BIO-RAD LABORATORIES, INC.
      • 16.1.8.1 Business overview
      • 16.1.8.2 Products offered
      • 16.1.8.3 Recent developments
        • 16.1.8.3.1 Product launches and approvals
    • 16.1.9 HORIBA
      • 16.1.9.1 Business overview
      • 16.1.9.2 Products offered
      • 16.1.9.3 Recent developments
        • 16.1.9.3.1 Product launches and approvals
    • 16.1.10 NIHON KOHDEN CORPORATION
      • 16.1.10.1 Business overview
      • 16.1.10.2 Products offered
      • 16.1.10.3 Recent developments
        • 16.1.10.3.1 Expansions
    • 16.1.11 EKF DIAGNOSTICS HOLDINGS PLC
      • 16.1.11.1 Business overview
      • 16.1.11.2 Products offered
      • 16.1.11.3 Recent developments
        • 16.1.11.3.1 Product launches and approvals
    • 16.1.12 BOULE
      • 16.1.12.1 Business overview
      • 16.1.12.2 Products offered
      • 16.1.12.3 Recent developments
        • 16.1.12.3.1 Product launches and approvals
        • 16.1.12.3.2 Deals
    • 16.1.13 F. HOFFMANN-LA ROCHE LTD
      • 16.1.13.1 Business overview
      • 16.1.13.2 Products offered
      • 16.1.13.3 Recent developments
        • 16.1.13.3.1 Deals
    • 16.1.14 BIOSYSTEMS DIAGNOSTICS
      • 16.1.14.1 Business overview
      • 16.1.14.2 Products offered
  • 16.2 OTHER PLAYERS
    • 16.2.1 DRUCKER DIAGNOSTICS
    • 16.2.2 ACCUREX
    • 16.2.3 STRECK
    • 16.2.4 NEOMEDICA
    • 16.2.5 EVERLIFE CPC
    • 16.2.6 MERIL
    • 16.2.7 SHENZHEN DYMIND BIOTECHNOLOGY CO., LTD.
    • 16.2.8 PZ CORMAY S.A.
    • 16.2.9 PIXCELL MEDICAL
    • 16.2.10 RAYTO LIFE AND ANALYTICAL SCIENCES CO.,LTD.
    • 16.2.11 ANALYTICON BIOTECHNOLOGIES GMBH

17 RESEARCH METHODOLOGY

  • 17.1 INTRODUCTION
  • 17.2 RESEARCH DATA
    • 17.2.1 SECONDARY DATA
      • 17.2.1.1 List of key secondary sources
      • 17.2.1.2 Key data from secondary sources
    • 17.2.2 PRIMARY RESEARCH
      • 17.2.2.1 Key data from primary sources
      • 17.2.2.2 Primary research objectives
      • 17.2.2.3 Key industry insights
      • 17.2.2.4 Breakdown of primaries
      • 17.2.2.5 List of primary interview participants
  • 17.3 MARKET SIZE ESTIMATION
    • 17.3.1 BOTTOM-UP APPROACH
    • 17.3.2 TOP-DOWN APPROACH
  • 17.4 GROWTH FORECAST
  • 17.5 DATA TRIANGULATION
  • 17.6 MARKET SHARE ASSESSMENT
  • 17.7 RESEARCH ASSUMPTIONS
  • 17.8 RESEARCH LIMITATIONS
  • 17.9 RISK ANALYSIS

18 APPENDIX

  • 18.1 DISCUSSION GUIDE
  • 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 18.3 CUSTOMIZATION OPTIONS
  • 18.4 RELATED REPORTS
  • 18.5 AUTHOR DETAILS
Product Code: MD 2479

List of Tables

  • TABLE 1 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • TABLE 3 POTENTIAL BIOMARKERS DETECTABLE BY NEXT-GENERATION HEMATOLOGY ANALYZERS
  • TABLE 4 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: UNMET NEEDS
  • TABLE 5 STRATEGIC FOCUS OF TIER-1/2/3 PLAYERS
  • TABLE 6 IMPACT OF PORTER'S FIVE FORCES ANALYSIS
  • TABLE 7 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • TABLE 8 EUROPE: MACROECONOMIC OUTLOOK
  • TABLE 9 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • TABLE 10 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • TABLE 11 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • TABLE 12 ROLE OF COMPANIES IN HEMATOLOGY ANALYZERS AND REAGENTS ECOSYSTEM
  • TABLE 13 PRICING TREND OF HEMATOLOGY INSTRUMENTS, BY REGION, 2023-2025 (USD THOUSAND)
  • TABLE 14 AVERAGE SELLING PRICE OF HEMATOLOGY ANALYZERS AND REAGENTS, BY PRICE RANGE, 2025 (USD THOUSAND)
  • TABLE 15 AVERAGE SELLING PRICE OF HEMATOLOGY REAGENTS & CONSUMABLES, BY KEY PLAYER, 2025 (USD THOUSAND)
  • TABLE 16 IMPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • TABLE 17 EXPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • TABLE 18 LIST OF KEY CONFERENCES AND EVENTS, 2026-2027
  • TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES IN MEDTECH INDUSTRY
  • TABLE 20 TARIFF-INDUCED PRICE INCREASES FOR HEALTHCARE PRODUCTS
  • TABLE 21 INNOVATIONS AND PATENT REGISTRATIONS, 2020-2024
  • TABLE 22 KEY COMPANIES IMPLEMENTING AI/GEN AI IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
  • TABLE 23 KEY APPLICATIONS AND CLINICAL OUTCOMES ENABLED BY HEMATOLOGY ANALYZERS
  • TABLE 24 NORTH AMERICA: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
  • TABLE 25 EUROPE: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
  • TABLE 26 ASIA PACIFIC: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
  • TABLE 27 LATIN AMERICA: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
  • TABLE 28 MIDDLE EAST & AFRICA: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
  • TABLE 29 IMPACT OF CLIA 2024 ON HEMATOLOGY ANALYZERS AND REAGENTS MARKET
  • TABLE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
  • TABLE 31 BUYING CRITERIA, BY PRODUCT & SERVICE
  • TABLE 32 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: UNMET NEED ANALYSIS, BY END USER
  • TABLE 33 HEMATOLOGY ANALYZER SEGMENTATION, BY SYSTEM TYPE, PERFORMANCE, AND PRICING
  • TABLE 34 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024-2031 (USD MILLION)
  • TABLE 35 LOW-RANGE HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 36 HIGH-RANGE HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 37 MID-RANGE HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 38 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024-2031 (USD MILLION)
  • TABLE 39 STANDALONE ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 40 POINT-OF-CARE ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 41 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 42 HEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 43 HEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 44 HEMATOLOGY REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 45 HEMATOLOGY REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 46 HEMATOLOGY REAGENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 47 HEMATOLOGY CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 48 HEMATOLOGY CONTROLS & CALIBRATORS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 49 HEMATOLOGY SLIDE STAINERS & MAKERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 50 HEMATOLOGY INSTRUMENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 51 HEMATOLOGY INSTRUMENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 52 5-PART VS. 6-PART FULLY AUTOMATED HEMATOLOGY ANALYZERS
  • TABLE 53 5-PART & 6-PART FULLY AUTOMATED HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 54 3-PART FULLY AUTOMATED HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 55 POINT-OF-CARE & SEMI-AUTOMATED TESTING HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 56 HEMATOLOGY SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 57 HEMOSTASIS PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 58 HEMOSTASIS PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 59 HEMOSTASIS REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 60 HEMOSTASIS INSTRUMENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 61 HEMOSTASIS SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 62 IMMUNOHEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 63 IMMUNOHEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 64 IMMUNOHEMATOLOGY REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 65 IMMUNOHEMATOLOGY INSTRUMENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 66 IMMUNOHEMATOLOGY SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 67 HAEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 68 HEMORRHAGIC CONDITIONS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 69 INFECTIOUS DISEASES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 70 IMMUNE SYSTEM DISORDERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 71 BLOOD CANCER: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 72 ANEMIA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 73 OTHER APPLICATIONS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 74 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 75 COMMERCIAL SERVICE PROVIDERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 76 HOSPITAL LABORATORIES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 77 GOVERNMENT REFERENCE LABORATORIES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 78 RESEARCH & ACADEMIC INSTITUTES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 79 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 80 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 81 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 82 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 83 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 84 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 85 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 86 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024-2031 (USD MILLION)
  • TABLE 87 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 88 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024-2031 (USD MILLION)
  • TABLE 89 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 90 US: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 91 CANADA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 92 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 93 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 94 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 95 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 96 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 97 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 98 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024-2031 (USD MILLION)
  • TABLE 99 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 100 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024-2031 (USD MILLION)
  • TABLE 101 EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 102 GERMANY: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 103 FRANCE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 104 UK: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 105 ITALY: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 106 SPAIN: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 107 REST OF EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 108 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 111 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 114 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024-2031 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024-2031 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 118 CHINA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 119 JAPAN: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 120 INDIA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 121 AUSTRALIA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 122 SOUTH KOREA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 123 REST OF ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 124 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 125 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 126 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 127 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 128 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 129 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 130 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY PRICE RANGE, 2024-2031 (USD MILLION)
  • TABLE 131 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 132 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY USAGE TYPE, 2024-2031 (USD MILLION)
  • TABLE 133 LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 134 BRAZIL: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 135 MEXICO: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 136 REST OF LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 137 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 138 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 139 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 140 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 141 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 142 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 143 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024-2031 (USD MILLION)
  • TABLE 144 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 145 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024-2031 (USD MILLION)
  • TABLE 146 MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 147 GCC COUNTRIES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 148 REST OF MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 149 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2022-MARCH 2026
  • TABLE 150 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DEGREE OF COMPETITION, 2025
  • TABLE 151 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: REGION FOOTPRINT
  • TABLE 152 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: PRODUCT & SERVICE FOOTPRINT
  • TABLE 153 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: APPLICATION FOOTPRINT
  • TABLE 154 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: END USER FOOTPRINT
  • TABLE 155 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 156 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 157 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2026
  • TABLE 158 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DEALS, JANUARY 2022-MARCH 2026
  • TABLE 159 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: EXPANSIONS, JANUARY 2022-MARCH 2026
  • TABLE 160 SYSMEX CORPORATION: COMPANY OVERVIEW
  • TABLE 161 SYSMEX CORPORATION: PRODUCTS OFFERED
  • TABLE 162 SYSMEX CORPORATION: DEALS, JANUARY 2022-MARCH 2026
  • TABLE 163 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2022-MARCH 2026
  • TABLE 164 ABBOTT: COMPANY OVERVIEW
  • TABLE 165 ABBOTT: PRODUCTS OFFERED
  • TABLE 166 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2026
  • TABLE 167 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 168 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 169 DANAHER CORPORATION: DEALS, JANUARY 2022-NOVEMBER 2025
  • TABLE 170 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 171 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 172 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022- MARCH 2026
  • TABLE 173 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022- MARCH 2026
  • TABLE 174 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
  • TABLE 175 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED
  • TABLE 176 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-AUGUST 2025
  • TABLE 177 DIATRON: COMPANY OVERVIEW
  • TABLE 178 DIATRON: PRODUCTS OFFERED
  • TABLE 179 DIATRON: EXPANSIONS, JANUARY 2022-MARCH 2026
  • TABLE 180 DREW SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 181 DREW SCIENTIFIC: PRODUCTS OFFERED
  • TABLE 182 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 183 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
  • TABLE 184 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2026
  • TABLE 185 HORIBA: COMPANY OVERVIEW
  • TABLE 186 HORIBA: PRODUCTS OFFERED
  • TABLE 187 HORIBA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2026
  • TABLE 188 NIHON KOHDEN CORPORATION: COMPANY OVERVIEW
  • TABLE 189 NIHON KOHDEN CORPORATION: PRODUCTS OFFERED
  • TABLE 190 NIHON KOHDEN CORPORATION: DEALS, JANUARY 2022-MARCH 2026
  • TABLE 191 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
  • TABLE 192 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED
  • TABLE 193 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2026
  • TABLE 194 BOULE: COMPANY OVERVIEW
  • TABLE 195 BOULE: PRODUCTS OFFERED
  • TABLE 196 BOULE: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2026
  • TABLE 197 BOULE: DEALS, JANUARY 2022-MARCH 2026
  • TABLE 198 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 199 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
  • TABLE 200 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 201 BIOSYSTEMS DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 202 BIOSYSTEMS DIAGNOSTICS: PRODUCTS OFFERED
  • TABLE 203 DRUCKER DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 204 ACCUREX: COMPANY OVERVIEW
  • TABLE 205 STRECK: COMPANY OVERVIEW
  • TABLE 206 NEOMEDICA: COMPANY OVERVIEW
  • TABLE 207 EVERLIFE CPC: COMPANY OVERVIEW
  • TABLE 208 MERIL: COMPANY OVERVIEW
  • TABLE 209 SHENZHEN DYMIND BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
  • TABLE 210 PZ CORMAY S.A.: COMPANY OVERVIEW
  • TABLE 211 PIXCELL MEDICAL: COMPANY OVERVIEW
  • TABLE 212 RAYTO LIFE AND ANALYTICAL SCIENCES CO.,LTD.: COMPANY OVERVIEW
  • TABLE 213 ANALYTICON BIOTECHNOLOGIES GMBH: COMPANY OVERVIEW
  • TABLE 214 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RESEARCH ASSUMPTIONS
  • TABLE 215 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RISK ANALYSIS

List of Figures

  • FIGURE 1 HEMATOLOGY ANALYZERS AND REAGENTS MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DURATION CONSIDERED
  • FIGURE 3 HEMATOLOGY ANALYZERS AND REAGENTS MARKET SCENARIO
  • FIGURE 4 GLOBAL HEMATOLOGY ANALYZERS AND REAGENTS MARKET SIZE, 2024-2031
  • FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET, 2022-2026
  • FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF HEMATOLOGY ANALYZERS AND REAGENTS MARKET
  • FIGURE 7 HIGH-GROWTH SEGMENTS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET, 2026-2031
  • FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET DURING FORECAST PERIOD
  • FIGURE 9 INCREASING HEALTHCARE INVESTMENTS AND AWARENESS ABOUT EARLY DISEASE DIAGNOSIS TO DRIVE HEMATOLOGY ANALYZERS AND REAGENTS MARKET
  • FIGURE 10 NORTH AMERICA TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD
  • FIGURE 11 COMMERCIAL SERVICE PROVIDERS AND CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN ASIA PACIFIC IN 2025
  • FIGURE 12 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2026 TO 2031
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 14 PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 15 HEMATOLOGY ANALYZERS AND REAGENTS VALUE CHAIN ANALYSIS
  • FIGURE 16 HEMATOLOGY ANALYZERS AND REAGENTS ECOSYSTEM ANALYSIS
  • FIGURE 17 PRICING TREND OF HEMATOLOGY INSTRUMENTS, BY REGION, 2023-2025
  • FIGURE 18 AVERAGE SELLING PRICE OF HEMATOLOGY ANALYZERS AND REAGENTS, BY PRICE RANGE, 2025
  • FIGURE 19 IMPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS FOR TOP FIVE COUNTRIES, 2021-2025
  • FIGURE 20 EXPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS FOR TOP FIVE COUNTRIES, 2021-2025
  • FIGURE 21 TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESS
  • FIGURE 22 INVESTMENT AND FUNDING SCENARIO, 2019-2023
  • FIGURE 23 NUMBER OF DEALS, BY KEY PLAYER, 2019-2023
  • FIGURE 24 DEAL VALUES, BY KEY PLAYER, 2019-2023
  • FIGURE 25 PATENTS APPLIED AND GRANTED, 2016-2025
  • FIGURE 26 KEY AI/GEN AI USE CASES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
  • FIGURE 27 HEMATOLOGY ANALYZER AND REAGENTS MARKET: DECISION-MAKING FACTORS
  • FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
  • FIGURE 29 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • FIGURE 30 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: UNMET NEED ANALYSIS
  • FIGURE 31 NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET SNAPSHOT
  • FIGURE 32 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET SNAPSHOT
  • FIGURE 33 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: REVENUE ANALYSIS OF TOP FOUR PLAYERS, 2021-2025
  • FIGURE 34 MARKET SHARE ANALYSIS OF COMPANIES OFFERING HEMATOLOGY ANALYZERS AND REAGENTS, 2025
  • FIGURE 35 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RANKING OF KEY PLAYERS, 2025
  • FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 37 FINANCIAL METRICS (EV/EBITDA)
  • FIGURE 38 PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 39 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 40 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPANY FOOTPRINT
  • FIGURE 41 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 42 SYSMEX CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 43 ABBOTT: COMPANY SNAPSHOT (2025)
  • FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 45 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 46 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2025)
  • FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 48 HORIBA: COMPANY SNAPSHOT (2025)
  • FIGURE 49 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 50 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2024)
  • FIGURE 51 BOULE: COMPANY SNAPSHOT (2024)
  • FIGURE 52 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
  • FIGURE 53 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RESEARCH DATA
  • FIGURE 54 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RESEARCH DESIGN
  • FIGURE 55 DATA CAPTURED FROM SECONDARY SOURCES
  • FIGURE 56 PRIMARY SOURCES
  • FIGURE 57 CORE FINDINGS FROM INDUSTRY EXPERTS
  • FIGURE 58 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 59 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 60 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 61 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: BOTTOM-UP APPROACH
  • FIGURE 62 HEMATOLOGY ANALYZERS AND REAGENTS MARKET SIZE ESTIMATION (APPROACH 1)
  • FIGURE 63 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: TOP-DOWN APPROACH
  • FIGURE 64 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: MARKET SIZE ESTIMATION
  • FIGURE 65 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DATA TRIANGULATION
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!